AMH Equity Ltd decreased its holdings in iCAD, Inc. (NASDAQ:ICAD - Free Report) by 53.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 136,643 shares of the technology company's stock after selling 159,409 shares during the period. AMH Equity Ltd owned approximately 0.51% of iCAD worth $250,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in ICAD. Summit Trail Advisors LLC purchased a new stake in shares of iCAD in the 4th quarter valued at $214,000. Thompson Davis & CO. Inc. bought a new stake in iCAD during the 4th quarter valued at $31,000. Finally, waypoint wealth counsel raised its holdings in iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock worth $26,000 after purchasing an additional 4,400 shares in the last quarter. Hedge funds and other institutional investors own 24.61% of the company's stock.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of iCAD from a "sell" rating to a "hold" rating in a research report on Thursday, February 20th.
Read Our Latest Stock Report on iCAD
iCAD Price Performance
ICAD stock traded up $0.02 during trading on Friday, hitting $2.41. 205,964 shares of the stock traded hands, compared to its average volume of 571,512. iCAD, Inc. has a 1 year low of $1.18 and a 1 year high of $3.78. The firm's 50 day moving average is $2.55 and its two-hundred day moving average is $1.99. The stock has a market cap of $63.96 million, a price-to-earnings ratio of -18.54 and a beta of 1.47.
iCAD Company Profile
(
Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Recommended Stories
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
